Search research articles
Contact Us
Filters
Showing results (301-310 of 365) with videos related to
Page
of 37
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor
Nicholas Stock, Christopher Baccei, Gretchen Bain, et al.
Therapeutic Advances in Medical Oncology
|
March 16, 2026
A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design
Jingran Ji, Catherine M Crespi, Lisa Yee, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation
Gretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
Journal of Medicinal Chemistry
|
September 11, 2009
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)
John H Hutchinson, Yiwei Li, Jeannie M Arruda, et al.
Cancer
|
January 24, 2024
Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial
Bette J Caan, Justin C Brown, Catherine Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation
Daniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Breast Cancer Research and Treatment
|
July 8, 2024
A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer
Emily Liang, Michael Beshara, Haiyang Sheng, et al.
JAMA
|
June 12, 2019
Association of Blood Donor Sex and Prior Pregnancy With Mortality Among Red Blood Cell Transfusion Recipients
Gustaf Edgren, Edward L Murphy, Don J Brambilla, et al.
Journal of the American College of Surgeons
|
January 27, 2026
Surgical Trainee Familiarity and Knowledge of the Commission on Cancer (CoC) Operative Standards: A National Survey Study
Alison S Baskin, Elizabeth C Funk, Jack W Sample, et al.
American Heart Journal
|
August 8, 2023
Physician assessment of aortic stenosis severity, quantitative parameters, and long-term outcomes: Results from the KP-VALVE project
Matthew D Solomon, Grace Tabada, Sue Hee Sung, et al.
Page
of 37
Search research articles
Search
Showing results (301-310 of 365) with videos related to
Sort By:
Page
of 37
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor
Nicholas Stock, Christopher Baccei, Gretchen Bain, et al.
Therapeutic Advances in Medical Oncology
|
March 16, 2026
A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design
Jingran Ji, Catherine M Crespi, Lisa Yee, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation
Gretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
Journal of Medicinal Chemistry
|
September 11, 2009
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)
John H Hutchinson, Yiwei Li, Jeannie M Arruda, et al.
Cancer
|
January 24, 2024
Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial
Bette J Caan, Justin C Brown, Catherine Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation
Daniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Breast Cancer Research and Treatment
|
July 8, 2024
A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer
Emily Liang, Michael Beshara, Haiyang Sheng, et al.
JAMA
|
June 12, 2019
Association of Blood Donor Sex and Prior Pregnancy With Mortality Among Red Blood Cell Transfusion Recipients
Gustaf Edgren, Edward L Murphy, Don J Brambilla, et al.
Journal of the American College of Surgeons
|
January 27, 2026
Surgical Trainee Familiarity and Knowledge of the Commission on Cancer (CoC) Operative Standards: A National Survey Study
Alison S Baskin, Elizabeth C Funk, Jack W Sample, et al.
American Heart Journal
|
August 8, 2023
Physician assessment of aortic stenosis severity, quantitative parameters, and long-term outcomes: Results from the KP-VALVE project
Matthew D Solomon, Grace Tabada, Sue Hee Sung, et al.
Page
of 37